| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_523523e4857f980c860a0d49e77ed0ec |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-324
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-54
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-323
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-585 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-74
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-53 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-53
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-74 |
| filingDate |
2015-11-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2016-12-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4d2ea5076433a5cc3744f80fb826c9b5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_78a76a59a401c68d802b485eb898135e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_07685db48d10db764a512f01f1c9c1b1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d7916f0903746d2e8fb5ea0f55ca1dfc
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_93ab58d3d0725f7115d3f0b94ecf4a5e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bc4e4b72faf59ebecd66f65f1b12191d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_457aac9ad18e13cc44a15d1cfaa62b21
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7afbf33f719b786822d1f8798f86dacb |
| publicationDate |
2016-12-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-9513301-B2 |
| titleOfInvention |
Method for risk stratification in stable coronary artery disease |
| abstract |
An in vitro method for the risk stratification of patients with stable arteriosclerosis, especially stable coronary artery disease, is disclosed wherein the concentration of procalcitonin is determined in the circulation of such patients using a highly sensitive PCT assay, and wherein within the range of PCT concentrations in the typical normal range of healthy individuals cutoff values are defined which distinguish groups of individual patients with stable arteriosclerosis in accordance with personal cardiac risk, and patients are allotted to one of said risk groups on the basis of their individual PCT concentrations. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9788798-B2 |
| priorityDate |
2007-08-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |